Dr. Faith Davies is a Professor of Medicine and Deputy Director of the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS) in Little Rock, Arkansas.
She is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refractory disease. Dr. Davies joined UAMS in July 2014 from the Institute of Cancer Research and the Royal Marsden Hospital, both in London. She earned her medical degree from the College of Medicine, University of Wales. She completed general medical training in Cardiff and Birmingham and hematology specialty training in Leeds and London.
Dr. Davies has focused for nearly two decades on the biology and treatment of multiple myeloma. Throughout her extensive career, her research has examined potential new drugs and new genetic technologies and their applications to myeloma. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into the clinical arena with a focus on individualized treatment.
Dr. Davies is a member of the American Society of Hematology, the American Association for Cancer Research, the British Society of Haematology, the Royal College of Physicians, UK, and the Royal College of Pathologists, UK.
She is widely published in leading peer-reviewed journals, including New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia and Lancet-Oncology. Dr. Davies is on the advisory boards for Celgene, Takeda, Amgen and BMS.